Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy

AAPS Journal

Volumn 16, Issue 5, 2014, Pages 975-985

  Joshi, Vijaya B ^a   Adamcakova Dodd, Andrea ^a   Jing, Xuefang ^a   Wongrakpanich, Amaraporn ^a   Gibson Corley, Katherine N ^b   Thorne, Peter S ^a   Salem, Aliasger K ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

allergy; CpG; Der p2; house dust mite; PLGA; vaccine

Indexed keywords

CYTOSINE PHOSPHATE GUANINE; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; PEPTIDE ANTIBODY; POLYGLACTIN; UNCLASSIFIED DRUG; DERP2 ALLERGEN, DERMATOPHAGOIDES PTERONYSSINUS; DRUG CARRIER; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; ENCAPSULATION; ENZYME RELEASE; EOSINOPHIL; HISTOPATHOLOGY; HOUSE DUST ALLERGY; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN MOTIF; RESPIRATORY TRACT ALLERGY; TH1 CELL; VACCINATION; ANIMAL; BLOOD; BRONCHIAL HYPERREACTIVITY; C3H MOUSE; CHEMISTRY; CPG ISLAND; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; KINETICS; LUNG; MEDICINAL CHEMISTRY; PATHOPHYSIOLOGY; PHARMACEUTICS; PROCEDURES; PYROGLYPHIDAE; RESPIRATORY HYPERSENSITIVITY; SOLUBILITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; BRONCHIAL HYPERREACTIVITY; CHEMISTRY, PHARMACEUTICAL; CPG ISLANDS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; KINETICS; LACTIC ACID; LUNG; MALE; MICE; MICE, INBRED C3H; PARTICLE SIZE; POLYGLYCOLIC ACID; PYROGLYPHIDAE; RESPIRATORY HYPERSENSITIVITY; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TH1 CELLS; VACCINATION; VACCINES;

EID: 84908356299     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9624-5     Document Type: Article

References (55)

1. Arbes Jr SJ, Cohn RD, Yin M, Muilenberg ML, Burge HA, Friedman W, et al. House dust mite allergen in US beds: results from the First National Survey of lead and allergens in housing. J Allergy Clin Immunol. 2003;111(2):408-14. (Pubitemid 36228565)
2. Busse WW, Lemanske Jr RF. Asthma. N Engl J Med. 2001;344(5):350-62. (Pubitemid 32107645)
3. Lambrecht BN, Hammad H. The airway epithelium in asthma. Nat Med. 2012;18(5):684-92.
4. Johnson JR, Wiley RE, Fattouh R, Swirski FK, Gajewska BU, Coyle AJ, et al. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. Am J Respir Crit Care. 2004;169(3):378-85. (Pubitemid 38134818)
5. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36.
6. Barnes PJ. Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol. 2012;129(1):48-59.
7. Incorvaia C, Di Rienzo A, Celani C, Makri E, Frati F. Treating allergic rhinitis by sublingual immunotherapy: a review. Ann Ist Super Sanita. 2012;48(2):172-6.
8. Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy. 2010;40(6):922-32.
9. Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther. 2013;13(11):1543-56.
10. Mazzarella G, Bianco A, Catena E, De Palma R, Abbate GF. Th1/Th2 lymphocyte polarization in asthma. Allergy. 2000;55:6-9. (Pubitemid 30430371)
11. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol. 1999;17:255-81. (Pubitemid 29241125)
12. Wohlleben G, Erb KJ. Atopic disorders: a vaccine around the corner? Trends Immunol. 2001;22(11):618-26. (Pubitemid 33043906)
13. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288-96 e3.
14. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1-55.
15. Arlian LG, Morgan MS, Neal JS. Dust mite allergens: ecology and distribution. Curr Allergy Asthma Rep. 2002;2(5):401-11.
16. Kidon MI, Chiang WC, Liew WK, Ong TC, Tiong YS, Wong KN, et al. Mite component-specific IgE repertoire and phenotypes of allergic disease in childhood: the tropical perspective. Pediatr Allergy Immunol. 2011;22(2):202-10.
17. Trompette A, Divanovic S, Visintin A, Blanchard C, Hegde RS, Madan R, et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature. 2009;457(7229):585-8.
18. Trombone APF, Tobias KRC, Ferriani VPL, Schuurman J, Aalberse RC, Smith AM, et al. Use of a chimeric ELISA to investigate immunoglobulin E antibody responses to Der p 1 and Der p 2 in mite-allergic patients with asthma, wheezing and/or rhinitis. Clin Exp Allergy. 2002;32(9):1323-8. (Pubitemid 35024959)
19. Tan LK, Huang CH, Kuo IC, Liew LM, Chua KY. Intramuscular immunization with DNA construct containing Der p 2 and signal peptide sequences primed strong IgE production. Vaccine. 2006;24(29-30):5762-71. (Pubitemid 43928188)
20. Huang TJ, MacAry PA, Eynott P, Moussavi A, Daniel KC, Askenase PW, et al . Allergen-specific Th1 cells counteract efferent Th2 cell-dependent bronchial hyperresponsiveness and eosinophilic inflammation partly via IFN-gamma. J Immunol. 2001;166(1):207-17. (Pubitemid 32038434)
21. Kline JN, Krieg AM. Toll-Like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 2008;21(8):434-9.
22. Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev. 2009;61(3):256-62.
23. Pulsawat P, Pitakpolrat P, Prompetchara E, Kaewamatawong T, Techakriengkrai N, Sirivichayakul S, et al. Optimization of a Der p 2-based prophylactic DNA vaccine against house dust mite allergy. Immunol Lett. 2013;151(1-2):23-30.
24. Heeg K, Zimmermann S. CpG DNA as a Th1 trigger. Int Arch Allergy Immunol. 2000;121(2):87-97. (Pubitemid 30130780)
25. Mo JH, Park SW, Rhee CS, Takabayashi K, Lee SS, Quan SH, et al . Suppression of allergic response by CpG motif oligodeoxynucleotide-house-dust mite conjugate in animal model of allergic rhinitis. Am J Rhinol. 2006;20(2):212-8.
26. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol. 2004;113(6):1144-51. (Pubitemid 38857998)
27. Kaburaki Y, Fujimura T, Kurata K, Masuda K, Toda M, Yasueda H, et al. Induction of Th1 immune responses to Japanese cedar pollen allergen (Cry j 1) in mice immunized with Cry j 1 conjugated with CpG oligodeoxynucleotide. Comp Immunol Microbiol Infect Dis. 2011;34(2):157-61.
28. Shirota H, Sano K, Kikuchi T, Tamura G, Shirato K. Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs. Am J Respir Cell Mol. 2000;22(2):176-82. (Pubitemid 30351480)
29. Gomez JMM, Fischer S, Csaba N, Kundig TM, Merkle HP, Gander B, et al. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm Res. 2007;24(10):1927-35. (Pubitemid 47389249)
30. Scholl I, Kopp T, Bohle B, Jensen-Jarolim E. Biodegradable PLGA particles for improved systemic and mucosal treatment of Type I allergy. Immunol Allergy Clin N Am. 2006;26(2):349-64. ix.
31. Martinez Gomez JM, Fischer S, Csaba N, Kundig TM, Merkle HP, Gander B, et al. A protective allergy vaccine based on CpG-and protamine-containing PLGA microparticles. Pharm Res. 2007;24(10):1927-35. (Pubitemid 47389249)
32. Zhang XQ, Dahle CE, Baman NK, Rich N, Weiner GJ, Salem AK. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother. 2007;30(5):469-78. (Pubitemid 46988080)
33. Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine delivery systems: size matters. AAPS J. 2013;15(1):85-94.
34. Thorne PS, McCray PB, Howe TS, O'Neill MA. Early-onset inflammatory responses in vivo to adenoviral vectors in the presence or absence of lipopolysaccharide-induced inflammation. Am J Respir Cell Mol. 1999;20(6):1155-64. (Pubitemid 129503233)
35. George CL, White ML, Kulhankova K, Mahajan A, Thorne PS, Snyder JM, et al. Early exposure to a nonhygienic environment alters pulmonary immunity and allergic responses. Am J Physiol Lung Cell Mol Physiol. 2006;291(3):L512-22. (Pubitemid 44343729)
36. De S, Robinson DH. Particle size and temperature effect on the physical stability of PLGA nanospheres and microspheres containing Bodipy. AAPS PharmSciTech. 2004;5(4):e53.
37. Gregory LG, Lloyd CM. Orchestrating house dust mite-associated allergy in the lung. Trends Immunol. 2011;32(9):402-11.
38. Wang X, Yang Q, Wang P, Luo L, Chen Z, Liao B, et al. Derp2-mutant gene vaccine inhibits airway in flammation and upregulates Toll-like receptor 9 in an allergic asthmatic mouse model. Asian Pac J Allergy Immunol. 2010;28(4):287-93.
39. Daan de Boer J, Roelofs JJ, de Vos AF, de Beer R, Schouten M, Hommes TJ, et al. Lipopolysaccharide inhibits Th2 lung inflammation induced by house dust mite allergens in mice. Am J Respir Cell Mol. 2013;48(3):382-9.
40. Sumino K, Sugar EA, Irvin CG, Kaminsky DA, Shade D, Wei CY, et al. Methacholine challenge test: diagnostic characteristics in asthmatic patients receiving controller medications. J Allergy Clin Immunol. 2012;130(1):69-75 e6.
41. Akinbami LJ, Moorman JE, Bailey C, Zahran HS, King M, Johnson CA, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. NCHS Data Brief. 2012;94:1-8.
42. Bharadwaj AS, Bewtra AK, Agrawal DK. Dendritic cells in allergic airway in flammation. Can J Physiol Pharmacol. 2007;85(7):686-99. (Pubitemid 350033267)
43. Suzuki K, Kaminuma O, Yang L, Takai T, Mori A, Umezu-Goto M, et al. Prevention of allergic asthma by vaccination with transgenic rice seed expressing mite allergen: induction of allergen-specific oral tolerance without bystander suppression. Plant Biotechnol J. 2011;9(9):982-90.
44. Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A, et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol. 2006;117(6):1470-6. (Pubitemid 43795737)
45. Standley SM, Mende I, Goh SL, Kwon YJ, Beaudette TT, Engleman EG, et al. Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity. Bioconjug Chem. 2007;18(1):77-83. (Pubitemid 46145996)
46. O'Hagan DT, Rappuoli R. Novel approaches to pediatric vaccine delivery. Adv Drug Deliv Rev. 2006;58(1):29-51.
47. Shen J, Burgess DJ. Drugs for long acting injections and implants. In: Wright JC, Burgess DJ, editors. Long acting injections and implants. New York: Springer; 2012. p. 73-92.
48. Hamdy S, Haddadi A, Hung RW, Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev. 2011;63(10-11):943-55.
49. Scholl I, Weissenbock A, Forster-Waldl E, Untersmayr E, Walter F, Willheim M, et al. Allergen-loaded biodegradable poly (D, L-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse model. Clin Exp Allergy. 2004;34(2):315-21. (Pubitemid 38315270)
50. Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Müller P, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy. 2009;39(4):562-70.
51. van Ree R, Antonicelli L, Akkerdaas JH, Garritani MS, Aalberse RC, Bonifazi F. Possible induction of food allergy during mite immunotherapy. Allergy. 1996;51(2):108-13. (Pubitemid 26173576)
52. Bosnjak B, Stelzmueller B, Erb KJ, Epstein MM. Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res. 2011;12:114.
53. Tang MLK, Powell CVE. Childhood asthma as an allergic disease: rationale for the development of future treatment. Eur J Pediatr. 2001;160(12):696-704.
54. Pulsawat P, Pitakpolrat P, Prompetchara E, Kaewamatawong T, Techakriengkrai N, Sirivichayakul S, et al. Optimization of a Der p 2-based prophylactic DNA vaccine against house dust mite allergy. Immunol Lett. 2013;151(1-2):23-30.
55. Zhang F, Huang G, Hu B, Song Y, Shi Y. Induction of immune tolerance in asthmatic mice by vaccination with DNA encoding an allergen-cytotoxic T lymphocyte-associated antigen 4 combination. Clin Vaccine Immunol: CVI. 2011;18(5):807-14.